Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.

Simulations Plus Trading Down 0.9 %

Simulations Plus stock traded down $0.28 during trading hours on Friday, reaching $30.68. 276,743 shares of the stock were exchanged, compared to its average volume of 130,076. The stock has a 50 day moving average of $33.08 and a two-hundred day moving average of $40.63. The company has a market cap of $613.91 million, a P/E ratio of 63.92 and a beta of 0.69. Simulations Plus has a twelve month low of $29.37 and a twelve month high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The company’s revenue was up 19.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.18 EPS. On average, analysts expect that Simulations Plus will post 0.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SLP shares. Craig Hallum reiterated a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday. KeyCorp started coverage on shares of Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 price target for the company. JMP Securities began coverage on shares of Simulations Plus in a research note on Tuesday, July 16th. They issued a “market perform” rating on the stock. Finally, BTIG Research lowered their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $54.50.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total value of $625,200.00. Following the transaction, the director now owns 3,481,592 shares in the company, valued at $108,834,565.92. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 60,750 shares of company stock worth $2,145,055 in the last quarter. Insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.